RxDoctor Payments Data

Mohamed Nasser, MD

Internal Medicine · Detroit, MINPI 1558890277

Payments from drug & device makers

$975in general payments, 2019–2025

Across 37 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$385
  • GSK$195
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • Exact Sciences$46
  • Neurelis, Inc.$28
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$329,989
Medicare patients
458
Services billed
2,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$19,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,709
JardianceEmpagliflozin16$10,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,178
Albuterol Sulfate HfaAlbuterol Sulfate38$1,140
Atorvastatin Calcium85$556
Nifedipine ErNifedipine28$449
Levetiracetam17$333
Gabapentin24$268
Pantoprazole Sodium47$253
Bumetanide15$247
Carvedilol59$225
Metoprolol Succinate31$215
Hydralazine Hcl34$209
Losartan Potassium32$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$195$15,70921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →